Mylan Presents Equivalence and Device Usability Data on WixelaTM InhubTM Compared to Advair Diskus® at American Thoracic Society International Conference
(WorldNews Health)

HERTFORDSHIRE, England, and PITTSBURGH, May 18, 2019/PRNewswire / -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced four scientific abstracts from the WixelaTM InhubTM (fluticasone propionate and salmeterol inhalation powder, USP) development program that will be presented at the 2019 American Thoracic Society (ATS) International Conference in Dallas, May 17- May 22. The data, available for the first time publicly, further supports the U.S. Food and Drug Administration`s approval in January 2019of Mylan`s Abbreviated New Drug Application for Wixela Inhub, which is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD). Mylan...